| Literature DB >> 24740136 |
Omar Y Mian1, Ashwin N Ram, Richard Tuli, Joseph M Herman.
Abstract
Pancreatic ductal adenocarcinoma is a highly lethal cancer that is rarely curable at the time of presentation. Unfortunately, most patients are diagnosed with either metastatic or locally advanced disease, which is not amenable to surgery owing to the high likelihood of incomplete resection. Given the generally poor prognosis with propensity for metastatic failure greater than that for local failure, treatment options are variable, and include chemotherapy, radiotherapy, targeted therapies, and combinations thereof. This review summarizes the current evidence for definitive management of locally advanced pancreatic adenocarcinoma, as well as the role of palliative therapies. Future directions, including the development of predictive biomarkers and novel systemic agents, are also discussed.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24740136 DOI: 10.1007/s11912-014-0388-y
Source DB: PubMed Journal: Curr Oncol Rep ISSN: 1523-3790 Impact factor: 5.075